Company intelligence / Profile preview

1cBio, Inc.

San Francisco Bay Area, California, United States1cbio.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

The company’s most advanced programs are an oral ENPP1 inhibitor for hypophosphatasia and a selective PARP1 inhibitor. Both have started IND-enabling studies. OC‑3 (PARP inhibitor) targets HR-deficient and HR-proficient tumors in breast, prostate, and pancreatic cancers. OC‑1 (ENPP1 inhibitor) has completed GLP toxicology studies and aims to enter clinical trials in the second half of 2025[4]. No clinical results yet; all programs are preclinical or IND-enabling.

Therapeutic areas: OncologyRare Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

1cBio CDK7 inhibitor

Preclinical

Partnerships

Alesta Therapeutics – exclusive global licensing agreement for OC–1 in hypophosphatasia[4].

Beyond the preview

Go deeper on 1cBio, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1cBio, Inc..

Explore the full profile